REPL
Replimune Group, Inc.
Key Financials
Net Income
$-247297000
↓ 14.6%
Revenue
$0
N/A
Operating Income
$-261627000
↓ 11.4%
Total Assets
$551.3M
↑ 13.0%
Total Liabilities
$135.5M
↑ 19.7%
EPS (Diluted)
$-3.07
↑ 5.2%
Shareholders' Equity
$415.8M
↑ 11.0%
Cash & Equivalents
$111.1M
↑ 49.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/13/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
| 4 | 4/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | REPL |
| Company Name | Replimune Group, Inc. |
| CIK | 1737953 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | (781) 222-9600 |